Evaluation of Protective Effects of Folinic Acid and Gonadotropin-Releasing Hormone Agonist and Antagonist Against Methotrexate Toxicity in Rats

被引:1
|
作者
Atakul, Tolga [1 ]
Oner, Gokalp [2 ]
Turan, Ozgur Deniz [1 ]
Celik, Serkan Yasar [3 ]
Yilmaz, Mustafa [4 ]
Yuksel, Hasan [1 ]
Demirci, Buket [5 ]
机构
[1] Adnan Menderes Univ, Dept Obstet & Gynecol, Fac Med, Aydin, Turkey
[2] Mem Kayseri Hosp, Clin Obstet & Gynecol, Kayseri, Turkey
[3] Mugla Sitki Kocman Univ, Dept Pathol, Fac Med, Mugla, Turkey
[4] Adnan Menderes Univ, Dept Biochem, Fac Med, Aydin, Turkey
[5] Adnan Menderes Univ, Dept Pharmacohol, Fac Med, Aydin, Turkey
关键词
Methotrexate; ovarian reserve; anti-mullerian hormone; gonadotropin-releasing hormone; folinic acid; ANTI-MULLERIAN HORMONE; SINGLE-DOSE METHOTREXATE; INDUCED OVARIAN DAMAGE; ECTOPIC PREGNANCY; RESERVE; WOMEN; SALPINGECTOMY; CHEMOTHERAPY; FERTILITY; APOPTOSIS;
D O I
10.4274/BMJ.galenos.2021.55265
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: A single dose of the folic acid antagonist methotrexate (MIX) is commonly used in ectopic pregnancy. However, the safety of MTX therapy on the ovarian reserve is still controversial. This study aimed to evaluate the use of folinic acid, a gonadotropin-releasing hormone (GnRH) antagonist, and a GnRH agonist on single-dose MTX-induced rat ovarian toxicity. Methods: A total of 40 Wistar albino rats were randomly divided into five equal groups. Then, all rats were administered MTX intramuscularly. While only physiological saline solution was administered to the control group, only MTX was administered to the MTX group. After 24 h of MTX administration, the MTX + leucovorin group received leucovorin. The MTX + GnRHa group received triptorelin acetate and MTX simultaneously. The MTX + GnRHant group received cetrorelix acetate with MTX. Results: The anti-mullerian hormone (AMH) level was similar in the control, MTX, MTX + GnRHa, MTX + GnRHant, and MTX + folinic acid groups. The number of primordial follicles was lower in the MTX group than in the control group (p=0.004), whereas this number in the other groups was similar to that in the control group. AMH levels in the MTX + folinic acid (p=0.001) and MTX + GnRHa (p=0.002) groups were higher than those in the MTX group. The number of primordial, primary, secondary and tertiary follicles was significantly higher in the MTX + folinic acid, MTX + GnRHa, and MTX + GnRHant groups than that in the MTX group. Conclusions: To the best of our knowledge, this is the first experimental study that can be benefited to minimize the damaging impacts of singledose MTX administration on ovarian reserve and AMH levels. Although the negative impact of single-dose MTX on ovarian reserve is known, our results show that this effect can be minimized by the concurrent administration of GnRHa, GnRHant, or folinic acid. The findings of the present study need to be confirmed with more extensive laboratory studies as well as with randomized controlled clinical studies
引用
收藏
页码:167 / 172
页数:6
相关论文
共 50 条
  • [41] Protective effect of gonadotropin-releasing hormone agonist against chemotherapy-induced ovarian dysfunction: A meta-analysis
    Zheng, Fei
    Zhu, Bin
    Feng, Qingjing
    Wu, Lili
    Cui, Yuechong
    Liu, Yumo
    Wang, Yingqian
    [J]. ONCOLOGY LETTERS, 2019, 17 (06) : 5319 - 5326
  • [42] EFFECTS OF A GONADOTROPIN-RELEASING HORMONE ANTAGONIST ON GONADOTROPIN-SECRETION AND GONADAL DEVELOPMENT IN NEONATAL PIGS
    ZIECIK, AJ
    ESBENSHADE, KL
    BRITT, JH
    [J]. JOURNAL OF REPRODUCTION AND FERTILITY, 1989, 87 (01): : 281 - 289
  • [43] Effects of long-term gonadotropin-releasing hormone agonist treatment on the pregnancy
    Tamura, H.
    Tamura, I.
    Maekawa, R.
    Asada, H.
    Sugino, N.
    [J]. HUMAN REPRODUCTION, 2012, 27
  • [44] THE EFFECTS OF COMBINING NORETHINDRONE WITH A GONADOTROPIN-RELEASING HORMONE AGONIST IN THE TREATMENT OF SYMPTOMATIC ENDOMETRIOSIS
    SURREY, ES
    GAMBONE, JC
    LU, JKH
    JUDD, HL
    [J]. FERTILITY AND STERILITY, 1990, 53 (04) : 620 - 626
  • [45] EFFECTS OF GONADOTROPIN-RELEASING HORMONE AGONIST ON UTERINE FIBROIDS AND BONE-DENSITY
    BIANCHI, G
    COSTANTINI, S
    ANSERINI, P
    ROVETTA, G
    MONTEFORTE, P
    MENADA, MV
    FAGA, L
    DECECCO, L
    [J]. MATURITAS, 1989, 11 (03) : 179 - 185
  • [46] THE STIMULATORY AND DOWN-REGULATORY EFFECTS OF A GONADOTROPIN-RELEASING HORMONE AGONIST IN MAN
    HEBER, D
    BHASIN, S
    STEINER, B
    SWERDLOFF, RS
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1984, 58 (06): : 1084 - 1088
  • [47] SUPPRESSION OF PITUITARY-TESTIS FUNCTION IN RATS TREATED NEONATALLY WITH A GONADOTROPIN-RELEASING HORMONE AGONIST AND ANTAGONIST - ACUTE AND LONG-TERM EFFECTS
    KOLHO, KL
    HUHTANIEMI, I
    [J]. JOURNAL OF ENDOCRINOLOGY, 1989, 123 (01) : 83 - 91
  • [48] Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin-releasing hormone agonist
    Ozcelik, Bulent
    Turkyilmaz, Cagdas
    Ozgun, Mahmut Tuncay
    Serin, Ibrahim Serdar
    Batukan, Cem
    Ozdamar, Saim
    Ozturk, Ahmet
    [J]. FERTILITY AND STERILITY, 2010, 93 (05) : 1609 - 1614
  • [49] Acute gonadotropin-releasing hormone agonist treatment enhances extinction memory in male rats
    Maeng, L. Y.
    Taha, M. B.
    Cover, K. K.
    Glynn, S. S.
    Murillo, M.
    Lebron-Milad, K.
    Milad, M. R.
    [J]. PSYCHONEUROENDOCRINOLOGY, 2017, 82 : 164 - 172
  • [50] Enhancement of A spermatogonial proliferation and differentiation in irradiated rats by gonadotropin-releasing hormone antagonist administration
    Shuttlesworth, GA
    De Rooij, DG
    Huhtaniemi, I
    Reissmann, T
    Russell, LD
    Shetty, G
    Wilson, G
    Meistrich, ML
    [J]. ENDOCRINOLOGY, 2000, 141 (01) : 37 - 49